Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 17/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 14/20 | 0.59 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | CFTR | P13569 | 1/20 | 0.35 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3300639 | 0.81 | ADORA2A (0.63) | ADORA2AADORA1 | |
| SCHEMBL3304867 | 0.79 | ADORA2A (0.52) | ADORA2AADORA1 | |
| SCHEMBL3302817 | 0.78 | ADORA2A (0.54) | ADORA2AADORA1ADORA2B | |
| SCHEMBL3300633 | 0.75 | ADORA2A (0.63) | ADORA2AADORA1 | |
| SCHEMBL3348820 | 0.73 | ADORA2A (0.81) | ADORA2AADORA1 | |
| SCHEMBL3345101 | 0.72 | HSP90AB1 (0.43) | ADORA2AADORA1HSP90AB1 | |
| SCHEMBL3348239 | 0.71 | ADORA2A (0.70) | ADORA2AADORA1HSP90AB1 | |
| SCHEMBL22573724 | 0.71 | HPGDS (0.41) | ADORA2AADORA1ADORA2BCFTR | |
| SCHEMBL3302309 | 0.70 | ADORA2A (0.65) | ADORA2AADORA1 | |
| SCHEMBL13389563 | 0.70 | ADORA2A (0.76) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010045008-A1 | AMIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-22 | — | — | WO | disclosed |